Qingdao Saber Technology Pharmaceutical: difference between revisions

Diff·revision 9 → 10·21:04, 2 Sep 2025

Difference between revision 9 and revision 10 of Qingdao Saber Technology Pharmaceutical. 12 lines changed; the page grew by 936 bytes.

Revision 9 — 02:29, 21 Aug 2025 BatchNumberBede (talk) typo 6,613 bytes +1,063	Revision 10 — 21:04, 2 Sep 2025 CheckSumChase (talk) fix indentation in the source 7,549 bytes +936
47	\| Raw materials and oils \| Bulk \| Certificate; specification sheet on request \|	47	\| Raw materials and oils \| Bulk \| Certificate; specification sheet on request \|
48		48
+		49	The catalogue follows the sector pattern. Documentation is better on the peptide lines than the bulk lines, as on most of these articles.{{r\|reports}}
+		50
49	== Independent testing record ==	51	== Independent testing record ==
50	Submitted reports on QST material to July 2026 are fewer than for the larger entries, reflecting a smaller reported customer base rather than a quality finding.{{r\|reports}} Reported [[Area percent purity\|area percent]] figures have been high in most cases.	52	Submitted reports on QST material to July 2026 are fewer than for the larger entries, reflecting a smaller reported customer base rather than a quality finding.{{r\|reports}} Reported [[Area percent purity\|area percent]] figures have been high in most cases.
51		53
+		54	Readers should note a limitation of the purity figure itself rather than of any particular report: an [[Area percent purity\|area percent]] result is obtained on what dissolved and went into the injector, so it cannot describe anything that did not. Appearance on reconstitution is therefore a separate observation from purity and is reported separately on the certificates in this set, which is the arrangement that lets a purchaser check both.{{r\|usp1503}}
+		55
52	== References ==	56	== References ==
53	{{reflist}}	57	{{reflist}}
⋮		⋮
56	<ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref>	60	<ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref>
57	<ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref>	61	<ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref>
+		62	<ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref>
58	<ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref>	63	<ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref>
59	<ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref>	64	<ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref>
+		65
+		66	== See also ==
+		67	* [[Certificate of analysis]]
+		68	* [[Third-party testing]]
+		69	* [[Area percent purity]]
+		70	* [[Peptide content]]
+		71	* [[Research use only]]
60		72
61	{{DEFAULTSORT:Qingdao Saber Technology Pharmaceutical}}	73	{{DEFAULTSORT:Qingdao Saber Technology Pharmaceutical}}